Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes who have been on metformin for the last 6 months and are taking a stable dose of metformin (≥ 1500 mg/d) as monotherapy for at least the last 3 months~* Male or female, 18-70 years of age~* All female patients must be surgically sterile or post-menopausal (at least 40 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or must agree to use two medically accepted methods of contraception including a barrier method. Depo contraceptives are excluded.~* Female patients must not be pregnant or lactating~* BMI ≥ 26 (patients of Asian Indian origin ≥ 22) kg/m2~* HbA1c ≥ 7.5%, ≤ 10.5%~* FPG ≥ 120 mg/dL, ≤ 240 mg/dL~Exclusion Criteria:~* History of diabetes secondary to pancreatitis or pancreatectomy~* Any history of ketoacidosis~* History of insulin use within last one year (insulin use while hospitalized is acceptable)~* Weight loss \> 10 pounds in the three months prior to screening visit~* History of TZD use (Actos® or Avandia®) within 6 months of screening visit~* History of TZD discontinuation due to side effect or lack of efficacy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MBX-102 400 (Type: EXPERIMENTAL): None
- MBX-102 600 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Actos (Type: ACTIVE_COMPARATOR): 30-45 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).